Oncology Products
International Demand for Oncology Drugs. There is an increasing demand worldwide for oncology medications, so pharmaceutical companies are seeing significant growth outside of their usual markets in the United States and Europe. Rising healthcare spending in Asian countries like China and Japan make medications more accessible. In India, expensive cancer care is becoming possible for those who can afford it, partially due to the influx of pharmaceutical companies outsourcing manufacturing to Indian factories.
Showing 1–9 of 62 results
-
ABIRAPRO (abiraterone acetate) Tablets USP 250mg, for oral use.
-
AVASTIN® (bevacizumab) Solution for intravenous infusion Initial U.S. Approval: 2004
-
BEOVU (brolucizumab-dbll) injection, for intravitreal injection. Initial U.S. Approval: 2019
-
BUPHENYL (sodium phenylbutyrate) Tablets
-
BYNFEZIA PEN (octreotide acetate) injection, for subcutaneous use. Initial U.S. Approval: 1988
-
CAPRELSA® (vandetanib) Tablets for Oral use. Initial U.S. Approval: 2011
-
COMETRIQ™ (cabozantinib) capsules, for oral use. Initial U.S. Approval: 2012
-
Crizalk (Crizotinib)
-
Cyendiv (nintedanib)